Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2002-01-18
2003-05-06
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S305000, C514S491000, C514S649000, C514S651000, C514S652000, C514S654000
Reissue Patent
active
RE038115
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to pharmacology. More specifically, the invention relates to compositions of matter useful for preparing medicaments for the treatment of various disorders.
A number of chronic disorders have symptoms which are known to be very difficult to treat, and often fail to respond to safe, non-addictive, and non-steroid medications. Such disorders, such as intractable coughing, fail to respond to conventional medicines and must be treated by such drugs as codeine, morphine, or the anti-inflammatory steroid prednisone. These drugs are unacceptable for long-term treatment due to dangerous side-effects, long-term risks to the patient's health, or the danger of addiction. Other disorders, such as dermatitis, have no satisfactory treatment for the severe itching and rash at this time. Drugs such as prednisone and even tricyclic antidepressants, as well as topical applications, have been tried, but do not appear to offer substantial and consistent relief.
Chronic pain due to conditions such as stroke, cancer, trauma, as well as neuropathic pain resulting from conditions such as diabetes and shingles (herpes zoster), for example, is also a problem which resists treatment. Chronic pain is estimated to affect millions of people. A variety of therapies for this type of pain have been tried, but there remains a need for safe and effective treatments.
The compound dextromethorphan, or (+)-3-methoxy-N-methylmorphinan, has been used as a cough suppressant ingredient in cough syrups. Dextromethorphan has also been tested as a potential therapeutic agent for stroke, and progressive neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis. However, the effectiveness of dextromethorphan for the treatment of any disorder has been limited because it is rapidly broken down by the liver and excreted in most individuals.
It is an object of the present invention to provide a combination of compounds useful for the preparation of medicaments which will effectively treat formerly intractable conditions not responsive to other medications. It is also an object of the present invention to provide medicaments which are safe, non-addictive, and relatively free of side-effects for patients suffering from long-term intractable conditions.
SUMMARY OF THE INVENTION
The present invention provides compounds which are useful in the preparation of medicaments for the treatment of a variety of disorders including intractable coughing, dermatitis, chronic pain, tinnitus and sexual dysfunction. These compounds are a therapeutically effective dosage of dextromethorphan and a therapeutically effective dosage of a second agent, an inhibitor of enzymatic dextromethorphan oxidation. This combination of compounds can be administered together, or individually. A preferred combination is dextromethorphan and the oxidative inhibitor quinidine. Inhibitors which may also be used include quinine, yohimbine, fluoxetine, haloperidol, ajmaline, lobeline, and pipamperone.
REFERENCES:
patent: 4316888 (1982-02-01), Nelson
patent: 5166207 (1992-11-01), Smith
patent: 5206248 (1993-04-01), Smith
patent: 5350756 (1994-09-01), Smith
patent: 5352683 (1994-10-01), Mayer et al.
patent: 5366980 (1994-11-01), Smith
patent: 5502058 (1996-03-01), Mayer et al.
Dickenson, A.H., “A cure for wind up: NMDA receptor antagonist as potential analgesics,”Trends in Pharm. Sci., 11:307-309 (1990).*
Dickenson, A.H., et al., “Dextromethorphan and levorphanol on dorsal horn nociceptive neurones in the rat,”Neuropharmacology, 30: 1303-1308 (1991).*
France, C. P., et al., “Analgesic Effects of Phencyclidine-Like Drugs in Rhesus Monkeys,”J. Pharmacol. Exp. Therapeutics, 250: 197-201 (1989).*
Mao, J., et al., “Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy,”Brain Research, 605: 164-168 (1993).*
McCarthy, J.P., “Some less familiar drugs of above,”Med. J. Australia 1971 (2): 1078-1081 (1971).*
McQuay, H. J., et al., “Dextromethorphan for the treatment of neurophatic pain: a double-blind randomised controlled crossover trial with integral n-of-1 deisgn,”Pain, 59: 127-133 (1994).*
Tortella, F.C., et al., “Dextromethorphan and neuromodulation: old drug coughs up new activities,”Trends in Pharm. Sci, 10: 501-507 (1989).*
Zhang et al. “Dextromethorphan: Enhancing its Systemic Availablity by Way of Low-dose QWuinidine-mediated Inhibition of Cytochrome P45O2D6,”Clin. Pharm. ? Ther., 51(6) :647-655 (1992).
Licht Jonathan M.
Smith Richard Alan
Center for Neurologic Study
Spivack Phyllis G.
LandOfFree
Dextromethorphan and an oxidase inhibitor for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dextromethorphan and an oxidase inhibitor for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dextromethorphan and an oxidase inhibitor for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3077131